| 1.9466 -0.013 (-0.68%) | 09-21 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.81 | 1-year : | 1.9 |
| Resists | First : | 1.55 | Second : | 1.62 |
| Pivot price | 1.5 |
|||
| Supports | First : | 1.42 | Second : | 1.18 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.5 |
| MA(100) : | 1.93 |
MA(250) : | 2.25  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.8 |
D(3) : | 26.3 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 7.67 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLSN ] has closed above bottom band by 13.1%. Bollinger Bands are 68.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.44 - 1.46 | 1.46 - 1.47 |
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Wed, 05 Nov 2025
Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer - PharmaVoice
Tue, 05 Aug 2025
Imunon puts COVID-19 vaccine on ice and seeks partner amid cash crunch - Fierce Biotech
Mon, 28 Jul 2025
IMUNON Announces Stock Dividend Boosting Shareholder Value - Yahoo Finance
Wed, 09 Jul 2025
Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials - Clinical Leader
Mon, 04 Nov 2024
SITC 2024 preview – late-breakers for Marengo and Indapta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Tue, 20 Sep 2022
Celsion rebrands to Imunon to reflect immunotherapy, COVID-19 vaccine ambitions - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | -0.39 |
| EPS Est This Year | -3.5 |
| EPS Est Next Year | -1.17 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -22.05 |
| EBITDA (p.s.) | -4.41921e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2017-05-29 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|